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Abstract
Background: Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI) anchored protein expressed
not only in prostate but also in pancreas and bladder cancer as shown by immunohistochemistry and mRNA
analysis. It has been targeted by monoclonal antibodies in preclinical animal models and more recently in a clinical
trial in prostate cancer patients. The biological role played in tumor growth is presently unknown. In this report we
have characterized the contribution of PSCA expression to tumor growth.
Methods: A bladder cell line was engineered to express a doxycycline (dox) regulated shRNA against PSCA. To
shed light on the PSCA biological role in tumor growth, microarray analysis was carried out as a function of PSCA
expression. Expression of gene set of interest was further analyzed by qPCR
Results: Down regulation of the PSCA expression was associated with reduced cell proliferation in vitro and in vivo.
Mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively
induced shRNA against PSCA as revealed by GFP expression. Pathway analysis of deregulated genes suggests a
statistical significant association between PSCA downregulation and activation of genes downstream of the IFNa/b
receptor.
Conclusions: These experiments established for the first time a correlation between the level of PSCA expression
and tumor growth and suggest a role of PSCA in counteracting the natural immune response.
Background
PSCA has been discovered a decade ago and has been
classified as a member of the Ly-6 family of GPI-
anchored cell surface proteins [1]. It is expressed in
most prostate cancer specimens, including high-grade
prostatic intraepithelial neoplasia, primary androgen-
dependent tumors, and hormone-refractory metastases.
PSCA levels are positively correlated with Gleason
grade, tumor stage, and biochemical recurrence. Its
expression is also particularly elevated in bone metasta-
sis. Finally, PSCA is strongly expressed in other malig-
nancies, including bladder and pancreatic cancers [2-6].
Different immunotherapy approaches targeting PSCA
have been tested in preclinical models including cancer
vaccine, therapeutic monoclonal antibodies and antibody
conjugated to toxic drugs [7-10]. More recently, a
human monoclonal antibody targeting PSCA has been
evaluated in a phase I clinical trial in prostate cancer
patients (AACR 2006).
Little information is available regarding the biological
role of PSCA. Proteins belonging to the Ly6 family are
involved in cell signaling events associated with thymic
lymphocyte differentiation, maturation and activation.
CD59, a member of this protein family, was shown to
play a role in the protection against complement
mediated lysis. In addition, it was found to be expressed
in tumor cells where it may play a role in evading anti
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does not appear to interfere with normal development
as PSCA knockout mice are viable. Additionally, cross-
ing of the PSCA knockout mice with prostate tumor
models driven by large T antigen did not increase pri-
mary tumor formation [12,13].
H e r et h eb i o l o g i c a lr o l eo fh u m a nP S C Aw a se v a l u -
ated using RNA interference and microarray analysis.
To establish a pharmacologic control over gene expres-
sion a shRNA against PSCA was identified and
expressed under the control of dox in a lentivirus sys-
tem [14]. Microarray analysis was utilized to identify
genes coregulated with PSCA in tumor xenografts.
Methods
Cell culture and generation of lentivirus vectors
The 293T and SW780 cell lines were cultured in Dul-
becco’s modified Eagle’s medium supplemented with
10% fetal calf serum. The lentivirus system for condi-
tional gene suppression with dox-inducible shRNAs uti-
lized has been described previously[14]. Briefly, in the
absence of dox, tTR-KRAB repressor binds to tetO and
suppresses H1-mediated shRNA transcription, thus
allowing normal expression of the cellular target gene.
In the presence of 10 μg/ml of dox, tTR-KRAB cannot
bind to tetO and hence shRNAs are produced, leading
to downregulation of PSCA. The green fluorescent pro-
tein (GFP) cDNA contained in the shRNA vector pro-
vides a monitoring device, as it is switched on by dox
treatment and GFPis expressed. All recombinant lenti-
viruses were produced by transient transfection in 293T
cells. Briefly, 293T cells were cotransfected with 20 μg
of pLUTHM-shPSCA3 plasmid, 15 μgo fp C M V -
ΔR8.91, and 5 μg of pMD2G-VSVG by calcium phos-
phate precipitation. After 16 h medium was changed,
and recombinant lentivirus vectors were harvested 48 h
later. FACS analysis was conducted as previously
described [15].
Viability assay
Cell viability was monitored using the CellTiter-Blue Via-
bility. The assay is based on the ability of living cells to
convert a redox dye (resazurin) into a fluorescent end
product (resorufin); 1 × 10
3 SW780-shPSCA and SW780-
shControl cells +/- Dox were plated in a 96 well plate in
parallel with the parental cell line SW780. Cells were
incubated at 37°c for 96 hrs, and fluorescence was subse-
quently monitored using a plate-reading fluorometer.
Tumor models
Six-week-old female CD-1 nude mice were purchased
from Charles River Laboratories and maintained in
accordance to Guidelines for the Care and Use of
Laboratory Animals in IRBM’s animal facility. This
study, was submitted and approved by the IRBM ethical
committee . Mice were injected subcutaneously (sc) in
the right flank with 2 × 10
6 SW780-shPSCA cells resus-
pended into 100 μL phosphate-buffered saline (PBS) and
Matrigel (1:1). Mice received 5% sucrose only or 5%
sucrose plus 0.2 mg/ml of dox for control and knock-
down cohorts, respectively. All water bottles were chan-
ged 3 times per week. Tumors were measured with
calipers and mice weighed twice per week. At the end of
the dosing study, or as indicated, appropriate tumor
samples were taken.
Microarray experiments
Total RNA from cell in culture was isolated with RNA-
zolB and then dissolved in RNase-free water. 25 μgo f
total RNA was treated with DNase using the Qiagen
RNase-free DNase kit and RNeasy spin columns. Then
RNA was dissolved in RNase-free water to a final con-
centration of 0.2 μg/μl. cRNA was generated using T7
RNA polymerase on 5 μg of total RNA and labeled with
Cy5 or Cy3 (Cy Dye, Amersham Pharmacia Biotech).
From each sample, 5 μg of labeled-RNA were co-hybri-
dized with 5 μg of a reference RNA (pool of two
untreated SW780 cell lines). Labeled cRNAs were frag-
mented to an average size of 50-100 nucleotides by
heating the samples to 60°C with 10 mM of zinc chlor-
ide and then adding an hybridization buffer containing 1
M NaCl, 0.5% sodium sarcosine, 50 mM MES, pH6.5,
and formamide to a final concentration of 30%. The
final volume was 3 ml at 40°C.
Samples were hybridized on a customized Agilent 44 k
array containing ~40,000 unique probes mapping to
~21,000 human genes. Each sample was hybridized in
duplicate with fluor reversal to systematically correct for
dye bias. After hybridization, slides were washed and
scanned using a confocal laser scanner (Agilent Tech-
nologies). The raw intensities obtained after scanning
were quantified, background-corrected and lowness nor-
malized. A weighted average ratio was computed for
dye-swapped pairs of hybridizations. Tumors were col-
lected in RNA later and processed for RNA extraction
as described previously [16]. Samples were hybridized
on a customized Affymetrix array containing ~38,000
probes mapping to ~21,000 human genes [17].
Hierarchical clustering
The microarray dataset was filtered before clustering in
order to select the 2,000 most variable probes. probes
with an absent call in more than 12 samples out of 14
were removed the 2,000 probes with the higher inter-
quartile range were retained for subsequent analysis.
Probes were hierarchically clustered using an average
linkage algorithm based on Pearson correlation
coefficients.
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Differences in average probe expression between the dox
+ (PSCA silencing) and dox-samples were computed by
1-way ANOVA. Probes differentially expressed between
the two classes were identified based on ANOVA
p-value < 0.001.
Gene set enrichment analysis
Groups of genes identified by 1-way ANOVA were com-
pared to a collection of annotated gene sets to identify
the functional classes that were significantly over-repre-
sented. The enrichment p-values were computed
according to the Fisher’s exact test. The gene sets were
obtained from public (Gene Ontology [18], KEGG [19],
Interpro [20], Panther [21], oPOSSUM [22] and com-
mercial sources (GeneGo (GeneGo Inc., St Joseph, MI,
USA), Ingenuity (Ingenuity Systems Inc, Mountain
View, CA, USA), TRANSFAC [23].
RT-PCR
Microarray findings were confirmed by real-time
reverse-transcription PCR (RT-PCR) using the average
value of mRNA from dox untreated SW780-shPSCA
samples as calibrator. Analysis of mRNA expression of
selected IFNa genes was performed using Applied Bio-
systems expression kit following manufacturers’ instruc-
tions. Expression values were computed using the
comparative CT method (ΔΔ CT) with GAPDH gene
expression value serving as normaliser.
Results
Establishment of cell clones with inducible shRNA against
PSCA
Published studies on PSCA have reported limited
expression in cell lines engineered, for the most part, to
express this protein ectopically [7,10]. Searching in a
microarray cell atlas comprising 20 cell lines of different
origins including prostate, pancreas and bladder revealed
al o wf r e q u e n c yo fP S C Ae x p r e s s i o n .T h ef e wc e l ll i n e s
with a detectable level of PSCA mRNA scored negative
when expression was analyzed at protein level by FACS
analysis (data not shown), suggesting that display of
PSCA on the cell surface is uncommon. We therefore
utilized a bladder cell line, SW780, which was shown to
express PSCA on the cell surface [8]. The cell line was
engineered to express different shRNA sequences
against PSCA (Table 1) or a control shRNA against luci-
ferase. To achieve a pharmacological controlled expres-
sion a dox inducible promoter was utilized in the
context of a lentivirus system [14]. One out of six
shRNA against PSCA showed a clear down regulation of
target gene expression and was therefore utilized to gen-
erate SW780-shPSCA, which expresses also the tet regu-
lator. Dox treatment resulted in 75% reduction of PSCA
expression as measured by FACS analysis. Since PSCA
is a membrane protein a further step was undertaken to
improve regulation of gene expression by sorting out
cells with low PSCA expression in the presence of dox.
This process led to the isolation of cells with a larger
interval of regulation mediated by dox treatment. To
control that the expression of shRNA was induced upon
dox treatment we took advantage of GFP gene, which is
cloned upstream of the shRNA and it was previously
utilized as a marker of shRNA expression [14]. FACS
analysis showed a quantitative GFP expression only in
dox treated SW780-shPSCA cells and a strong reduction
of PSCA expression (Figure 1A). These data suggest that
expression of shRNA specific for PSCA can be induced
and that it leads to almost 90% downregulation of the
target gene.
Biological effects of PSCA down-regulation in SW780 cells
To characterize the impact of PSCA expression on cell
growth, a viability assay was carried out. A statistical sig-
nificant reduction in cell viability was observed in dox
treated cells whereas no difference was observed in con-
trol transfected cells (Figure 1B).
To verify the impact of PSCA expression on SW780-
shPSCA tumor growth dox treatment was either started
in vitro one week in advance or at the time of cell
implantation. A statistical significant reduction in s.c.
tumor growth (p < 0.05) was observed in the cohort of
animals treated with dox with respect to controls
including also SW780-shCont treated with dox
(Figure 2A). Interestingly, tumors generated with cells
pretreated in vitro with dox were smaller than tumors
treated with dox only in vivo, although this difference
was not statistically significant. In contrast control
shRNA did not show any statistical reduction of tumor
growth. To confirm that shRNA against PSCA was
induced in vivo tumors were sacrificed at day 28 and
expression of shRNA was evaluated by looking at GFP
expression. Only dox-treated mice showed GFP expres-
sion in SW780-shPSCA tumors (Figure 2B). In line with
the shRNA expression, PSCA was down-regulated as
shown by IHC. All together these experiments indicate
that PSCA plays a critical role in the SW780-shPSCA
Table 1 shRNA sequences against PSCA
shRNA Sequence Coding Region N
1 CATCCTAACGCAAGTCTGATT No 497-515
2 GCAAGTCTGACCATGTATGTT No 506-524
3 GGCAGATCAGCTCTAGTGATT No 585-603
4 CAAGTCTGACCATGTATGTTT No 507-525
5 GCAAGAAGAACATCACGTGTT Yes 256-274
6 GTGACACCGACTTGTGCAATT Yes 277-295
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tumor mass with respect to dox untreated tumors.
Transcriptional data analysis
To gain some hints on the biological role played by
PSCA, expression profile was carried out in tumors.
Unsupervised hierarchical clustering of genome-wide
expression data showed that samples clustered accord-
ing to dox treatment (Figure 3A), thus demonstrating a
clear effect of the PSCA expression levels on transcrip-
tional programs. To identify the genes differentially
expressed in the two experimental conditions, a 1-way
ANOVA analysis was carried out. Out of the 37,586
probes represented on the array, 284 and 353 were
found to be respectively up- and down-regulated in
dox+ samples, as compared to dox-samples (ANOVA
p-value < 0.001). Similar microarray experiments were
also conducted in vitro showing a similar separation
between the two groups, according to dox treatment.
Comparison between the in vitro and in vivo data sets
revealed a statistical significant overlap for the
overexpressed genes (Table 2), although it may repre-
sent an underestimation due to the limited size of in
vitro observations.
The genes identified as differentially expressed were
analyzed by gene set enrichment analysis, using the
same method also used elsewhere [24]. In this way we
could monitor the pathways showing a global transcrip-
tional perturbation upon silencing of PSCA (Figure 3B).
We defined as up- or down-regulated the pathways
statistically enriched in the list of genes up- or down-
regulated, respectively, in the presence or absence of
treatment. A statistically significant enrichment was
observed between the list of genes up-regulated upon
PSCA silencing (dox+). The IFNa/b signaling pathway
resulted to be up-regulated upon PSCA silencing in the
in-vivo experiments but its up-regulation was not evi-
dent in the in vitro datase. Out of the 27 genes listed in
the Ingenuity database for interferon signaling 12 were
up-regulated in vivoa n d1in vitro,S T A T 2 .S i m i l a r
results were obtained using the GeneGo database to run
the analyses (8 out of 28 genes). In addition, the “anti-
gen presentation” pathway resulted as perturbed with
the highest statistical significance. Other immune related
pathways were also affected although at lower statistical
significance. In agreement with the reduced cell viability
in vitro (Figure 1B) and reduced tumor growth
(Figure 2A) the down-regulated pathways were “growth”
and “negative regulation of apoptosis”.
To measure by a more quantitative method the ampli-
tude of gene regulation, selected genes were analyzed by
qRT-PCR. As shown in Figure 4A, a subset of genes
belonging to IFNa/b pathway such as IFIT1, IFI27 and
IFI44L showed a statistical significant up-regulation (p <
0.001) in tumors where PSCA was down-regulated by
dox treatment. To exclude that expression of shRNA
per se could trigger expression of IFN pathway genes,
tumors expressing control shRNA were analyzed. No
statistical differences were observed with or without
control shRNA expression. Interestingly, qPCR analysis
of SW780-shPSCA in cell culture (Figure 4B) confirmed
the lack of induction of the IFNa genes regardless of
PSCA expression, suggesting a distinct role for PSCA in
the context of tumor growth.
Discussion
In this study, we have identified a correlation between
PSCA expression and tumor growth in vivo. High level
of PSCA mRNA and protein expression has been
observed in most primary prostate and pancreatic
human tumors and in particular in aggressive metastatic
forms. In bladder cancer, higher levels of PSCA expres-
sion correlated with increasing tumor grade [25] and
more recently genetic variants in this gene were asso-
ciated with cancer occurrence, although the biological
Figure 1 Characterization of SW780-shPSCA cells. A) FACS
analysis of SW780-shPSCA cells in physiological condition (black
line) or upon induction of shRNA against PSCA (red line): left panel
shows GFP expression, which is a marker of shRNA expression; right
panel shows PSCA expression, mean fluorescence intensity was
decreased from 333 to 35 upon expression of shRNA. B) Viability
assay in the presence of dox (empty) or without dox (filled) was
carried out using the CellTiter-Blue Viability assay as described in
material and methods. Error bars indicate standard error.
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Page 4 of 9Figure 2 SCA silencing inhibits SW780-shPSCA tumor growth. A) Balb/C nude mice were injected s.c. with SW780-shPSCA cells or SW780-
shCont cells. To further lower PSCA expression a group of mice was injected with SW780-shPSCA cells pretreated with dox in vitro for 1 week
(green line). Groups of 6-10 mice were injected with cells and treated as follow: SW780-shPSCA bearing mice not treated with dox (red) or
treated with dox (green and blue); SW780-shCont. Treated with dox (magenta) or not treated (black). B) At the end of the experiment SW780-
shPSCA tumors were collected and subjected to IHC analysis for PSCA expression (left panel) or analyzed for GFP expression (right panel).
Marra et al. BMC Cancer 2010, 10:129
http://www.biomedcentral.com/1471-2407/10/129
Page 5 of 9Figure 3 Identification of gene classes in SW780-shPSCA tumors and cells. To induce PSCA silencing mice or cell in culture were treated
with dox (dox +) or leaved untreated (dox -). A) Unsuprvised hierarchical clustering of tumors and cells showed that all samples clustered
according to dox treatment. Left dendogram shows results of six dox treated and eight untreated tumors collected at day 25 of tumor growth.
Right dendogram shows two independent experiments conducted with cells treated for one week in vitro with dox and compared to untreated
cells. B) Gene set enrichment of deregulated gene as a function of PSCA expression. Results of gene set enrichment analysis carried out in
SW780-shPSCA tumors (in-vivo) or in SW780-shPSCA cells in culture (in-vitro) according to PSCA expression.
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[26].
The observed tumor specific expression of PSCA has
prompted the development of therapeutic antibodies
specific for this membrane protein. Indeed, growth inhi-
bition has been observed upon antibody treatment of
cells transfected with vectors expressing PSCA or of
naturally expressing cell lines such as SW780. The pub-
lished studies are in agreement with the data reported
here indicating that reduced PSCA expression is asso-
ciated with lower viability [7]. Thus, based on these
published data, a better understanding of the biologic
role played by PSCA in tumor growth is warranted.
To shed light on PSCA role in tumor biology we com-
pared PSCA expression in different cell lines and found
expression on cell surface in few of them or in
explanted primary tumors. Thus, the bladder cell line
SW780 was engineered to obtain a pharmacological
controlled expression of PSCA and to study the impact
of reduced PSCA gene expression on cell viability and
tumor growth. Here, we report a direct correlation
between PSCA expression and tumor growth. Of note is
the observation that pretreatment with dox in vitro
further reduced tumor growth. This latter result may be
partially explained by the slow decay of PSCA displayed
on the cell membrane as indicated by FACS analysis.
A role for PSCA in tumor proliferation is further sup-
ported by the biological pathway analysis of gene expres-
sion profiling where a statistical significant association
with “negative regulation of apoptosis” and “growth” was
observed. Many of the pathways activated upon PSCA
downregulation control key immune functions. Activation
of IFNa/b signal transduction pathway was observed only
in SW780-shPSCA tumors (Figure 2B) and it was not
evident in tumors obtained upon injection of control
cells. In contrast, similar studies conducted with these
cell lines in vitro did not show induction of the pathway
suggesting that in the tumor context additional factors
such as those related to immune modulation may contri-
bute to the observed microarray signature. A quantitative
analysis of gene expression by qPCR confirmed overex-
pression of IFNa/b genes (Figure 4). The activation of
IFNa/b pathway only in vivo further supports the idea
that triggering of this pathway is not determined by an
intracellular mechanism related to double strand RNA, as
it has been previously reported. On the contrary, the data
suggest that IFNa/b activation is related to environmen-
tal signals. The activation of IFNa/b pathway is consis-
tent with a reduced tumor growth as previously shown
with recombinant IFNa [27,28] .
Nonetheless, further experiments are required to bet-
ter characterize the link between PSCA downregulation
and activation of immune pathways such as IFNa/b.I n
this direction it is worth mentioning a potential physical
Table 2 Genes differentially expressed upon reduction of
PSCA expression and overlap between in vitro and in
vivo dataset.
Genes in vitro in vivo overlap p-value
up regulated 123 208 8 0.0001
down regulated 119 234 3 0.19
Figure 4 Expression levels of selected IFNa/b pathway genes as a function of PSCA expression. Expression levels for IFI27, IFI44L and IFIT1
genes were measured in individual SW780-shPSCA tumors (n = 6-8) (A) or in SW780-shPSCA in cell culture conditions (B) with or without dox
treatment. Gene expression was measured by qPCR using the ΔΔ ct method. The average gene values in dox untreated mice served as
reference and GAPDH gene as normalizer. In black average values in SW780-shPSCA tumors and in white SW780-shCont.
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is a GPI-anchored protein located in lipid raft. IFNa/b
receptor can be brought into this subcellular compart-
ment upon interaction with its ligands [29]. Thus, PSCA
may counteract intracellular signaling exerted by the
IFNa/b receptor playing a role as a defense protein.
This biological role is reminiscent of the interfering role
played by PSCA homolog, CD59, in the complement
system [30]. Activation of the complement system is
tightly regulated and among the various regulators
CD59 has been identified as the single membrane regu-
lator of the terminal membrane attack complex. More-
over CD59 has been characterized as a negative
regulator of the T-cell response in mice. Although we
limited our qPCR confirmation only to IFNa/b pathway,
a statistical significant up regulation was observed also
for other immune pathways such as of MHC-1 pathway.
Given the pleiotropic effects of IFNa/b pathway it is
likely that some pathways, including MHC-1 presenta-
tion, may be affected downstream. A more in depth ana-
lysis would be required to answer this question. Finally
we cannot exclude that the correlations observed only
in tumors and not in cell culture are driven by unde-
fined factors that are not captured in the expression
profile and deserve further investigation.
Conclusions
The current findings suggest a role of PSCA in counter-
acting the natural immune response against cancer. This
information could help in design more effective experi-
ments in preclinical models not only with monoclonal
antibodies but also with approaches based on cancer
vaccine [31-35]. It would be of interest to correlate anti-
tumor efficacy of PSCA-targeting therapies as a function
of the natural immune response.
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